Halozyme Therapeutics Inc
$ 62.95
-2.64%
04 Dec - close price
- Market Cap 7,402,731,000 USD
- Current Price $ 62.95
- High / Low $ 66.00 / 61.70
- Stock P/E 13.28
- Book Value 4.29
- EPS 4.74
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.21 %
- ROE 1.25 %
- 52 Week High 79.50
- 52 Week Low 46.26
About
Halozyme Therapeutics, Inc. is an innovative biopharmaceutical company headquartered in San Diego, California, recognized for its groundbreaking drug delivery technologies that significantly enhance the effectiveness of existing therapies. Utilizing its proprietary ENHANZE® technology, Halozyme focuses on developing subcutaneous formulations that improve patient adherence and outcomes across a range of indications. The company strategically collaborates with industry-leading pharmaceutical partners, thereby expanding its therapeutic offerings and solidifying its role as a key player in the biotechnology sector. With a global operational footprint in the U.S., Europe, and Asia, Halozyme is well-positioned to meet the growing demand for more effective and patient-friendly therapeutic solutions.
Analyst Target Price
$76.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-28 | 2025-08-05 | 2025-05-06 | 2025-02-18 | 2024-10-31 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-06 | 2023-08-08 | 2023-05-09 | 2023-02-21 |
| Reported EPS | 1.72 | 1.54 | 1.11 | 1.26 | 1.27 | 0.91 | 0.79 | 0.82 | 0.75 | 0.74 | 0.47 | 0.48 |
| Estimated EPS | 1.61 | 1.23 | 0.94 | 1.1588 | 0.98 | 0.76 | 0.7 | 0.83 | 0.71 | 0.63 | 0.48 | 0.47 |
| Surprise | 0.11 | 0.31 | 0.17 | 0.1012 | 0.29 | 0.15 | 0.09 | -0.01 | 0.04 | 0.11 | -0.01 | 0.01 |
| Surprise Percentage | 6.8323% | 25.2033% | 18.0851% | 8.7332% | 29.5918% | 19.7368% | 12.8571% | -1.2048% | 5.6338% | 17.4603% | -2.0833% | 2.1277% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HALO
2025-10-18 14:50:01
This article provides a real-time signal analysis for Halozyme Therapeutics Inc. (NASDAQ: HALO) using AI models. It outlines key findings including sentiment, resistance levels, and a significant risk-reward short setup. The analysis presents institutional trading strategies and multi-timeframe signal strengths to guide potential trading decisions.
2025-10-17 15:02:13
This article from Zacks explains why Halozyme Therapeutics (HALO) is considered a strong value stock, highlighting its Zacks Rank, VGM Score, and Value Style Score. It details the methodology behind Zacks' Style Scores (Value, Growth, Momentum, and VGM) and how they complement the Zacks Rank to identify promising investment opportunities. HALO's attractive valuation metrics and positive earnings estimate revisions are presented as key reasons for its strong value recommendation.
2025-10-17 13:40:02
Halozyme Therapeutics (HALO) is identified as a strong value stock due to its impressive earnings and valuation fundamentals. The company boasts a Value Style Score of B and a positive Zacks Rank, with analysts revising earnings estimates upwards for fiscal 2025. This indicates a potentially undervalued stock with strong future prospects for value investors.
2025-10-17 13:40:02
Halozyme Therapeutics (HALO) is identified as a strong value stock due to its attractive valuation ratios, positive earnings estimates, and a favorable Zacks Rank and Style Scores. The article highlights the company's business in developing oncology treatments and licensing its ENHANZE drug delivery technology. Investors are encouraged to consider HALO for its fundamental strengths.
2025-10-15 11:10:08
HC Wainwright & Co. has reiterated its "Buy" rating for Halozyme Therapeutics (HALO) with a maintained price target of $90, reflecting continued confidence in the company. This follows several recent analyst upgrades and maintained ratings, suggesting strong investor sentiment. Wall Street analysts forecast an average target price of $77.63 for HALO, implying a 16.47% upside from its current price, with a consensus "Outperform" recommendation.
2025-10-15 08:04:22
The Maryland State Retirement & Pension System has acquired a new position valued at $310,000 in Halozyme Therapeutics, Inc. Several other hedge funds have also adjusted their holdings in the biopharmaceutical company, which has seen its stock trading up by 2.0%. Analysts have raised price targets for HALO, indicating a positive outlook.
